医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Osstem Implant Selects Dassault Systèmes’ “License to Cure for Medical Device” Industry Solution Experience to Expand in Global Markets

2016年06月28日 PM02:00
このエントリーをはてなブックマークに追加


 

VELIZY-VILLACOUBLAY, France

Dassault Systèmes (Euronext Paris: #13065, DSY.PA) (Paris:DSY), the 3DEXPERIENCE Company, world leader in 3D design software, 3D Digital Mock Up and Product Lifecycle Management (PLM) solutions, today announced that Osstem Implant Co., Ltd., a developer and manufacturer of medical device technologies, is using Dassault Systèmes’ “License to Cure for Medical Device” industry solution experience to expand its global market share in dental implant solutions.

The medical device industry has been plagued by safety and quality issues and product recalls that have led to increased regulatory scrutiny. As a result, many companies must dedicate more research and development expenditures to regulatory activities than to new product introductions.

Osstem Implant, with 22 offices worldwide and manufacturing facilities in the U.S. and South Korea, looked to expand its market share by balancing regulatory requirements with innovation. Specifically, it sought a unified, digital platform to manage unique device identifier (UDI), design change and quality assurance information it submits to regulatory approval organizations such as the U.S. Food and Drug Administration.

Based on the 3DEXPERIENCE platform, the “License to Cure for Medical Device” industry solution experience provides a collaborative, integrated business framework that accelerates the delivery of innovative, safe, and fully compliant medical devices. By eliminating traditionally disconnected processes and data, Osstem Implant has access to a single source of information and an end-to-end, traceable and compliant product development process directly linked to quality management. This helps minimize time to market and regulatory overhead.

“We selected Dassault Systèmes’ ‘License to Cure for Medical Device’ to help us better manage regulatory activities and new product development as we expand internationally and must meet different market requirements,” said Tae-Yong Kim, Head of Information System Management Team, Osstem Implant. “We can improve product development and project management efficiency and streamline the regulatory filing process for our dental implant solutions.”

“The ‘License to Cure for Medical Device’ industry solution experience transforms regulatory from a constraint into an asset and allows the organization to optimize quality and compliance efforts and reduce cost and time to market,” said Jean Colombel, Vice President Life Sciences Industry, Dassault Systèmes. “With a collaborative, end-to-end, fully traceable, fully compliant product development process that is directly linked to quality and regulatory information, companies can meet project challenges and accelerate the creation of advanced solutions for human health.”

For more information on Dassault Systèmes’ industry solution experiences for Life Sciences: http://www.3ds.com/industries/life-sciences/

About Dassault Systèmes
Dassault Systèmes, the 3DEXPERIENCE Company, provides business and people with virtual universes to imagine sustainable innovations. Its world-leading solutions transform the way products are designed, produced, and supported. Dassault Systèmes’ collaborative solutions foster social innovation, expanding possibilities for the virtual world to improve the real world. The group brings value to over 210,000 customers of all sizes, in all industries, in more than 140 countries. For more information, visit www.3ds.com.

3DEXPERIENCE, the Compass logo and the 3DS logo, CATIA, SOLIDWORKS, ENOVIA, DELMIA, SIMULIA, GEOVIA, EXALEAD, 3D VIA, BIOVIA, NETVIBES and 3DEXCITE are registered trademarks of Dassault Systèmes or its subsidiaries in the US and/or other countries.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160627006130/en/

CONTACT

Dassault Systèmes Press Contacts
Corporate / France
Arnaud
MALHERBE, +33 (0)1 61 62 87 73
arnaud.malherbe@3ds.com
or
North
America
Suzanne MORAN, +1 (781) 810 3774
suzanne.moran@3ds.com
or
EMEAR
Virginie
BLINDENBERG, +33 (0) 1 61 62 84 21
virginie.blindenberg@3ds.com
or
China
Grace
MU, +86 10 6536 2288
grace.mu@3ds.com
or
Japan
Yukiko
SATO, +81 3 4321 3841
yukiko.sato@3ds.com
or
Korea
Myoungjoo
CHOI, +82 10 8947 6493
myoungjoo.choi@3ds.com
or
India
Seema
SIDDIQUI, +91 1244 577 100
seema.siddiqui@3ds.com
or
AP
South
Tricia SIM, +65 6511 7954
tricia.sim@3ds.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • 三井化学开发全球首款灵活的高强度柔性无纺布AIRYFA™
  • APR应用制药研究公司参加第9届ChinaBio®合作论坛:依托瑞士创新产品和科学技术深耕中国市场
  • Dompé用于治疗中度或重度神经营养性角膜炎成人患者的Oxervate®(Cenegermin滴眼液)获得欧盟CHMP肯定意见
  • SCIEX Sponsored Award Recognizes Notable Contributions to Electrodriven Separations
  • LMDのV-Sensorがインドでバイタルサインを測定